Fig. 3. Overall survival from diagnosis of blast phase according to different subgroups.
A overall survival for patient with central nervous system (CNS) and/or extramedullary (EM) involvement compared to patients without CNS and extramedullary involvement; B Overall survival for patient with de novo blast phase (CML-BP) and blast phase evolving from a previous chronic phase (CML-CP); C overall survival according to disease phenotype (myeloid vs. lymphoid); D overall survival according to disease phase (de novo) and ELTS score at the time of chronic phase (ELTS low, ELTS intermediate, ELTS high) [low ELTS vs. de novo HR 1.09 [95% CI: 0.68–1.75], p = 0.713, low ELTS vs. intermediate ELTS HR 2.35 [95% CI 1.35–4.11], p = 0.003, low ELTS vs. high ELTS HR 2.75 [95% CI: 1.57–4.81], p < 0.001]. All p values have to be interpreted as exploratory.